JP2021523208A5 - - Google Patents
Info
- Publication number
- JP2021523208A5 JP2021523208A5 JP2020564227A JP2020564227A JP2021523208A5 JP 2021523208 A5 JP2021523208 A5 JP 2021523208A5 JP 2020564227 A JP2020564227 A JP 2020564227A JP 2020564227 A JP2020564227 A JP 2020564227A JP 2021523208 A5 JP2021523208 A5 JP 2021523208A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- item
- succinate
- approximately
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024031206A JP2024051160A (ja) | 2018-05-14 | 2024-03-01 | ピリミジン誘導体の医薬塩及び障害の処置方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671182P | 2018-05-14 | 2018-05-14 | |
| US201862671166P | 2018-05-14 | 2018-05-14 | |
| US62/671,182 | 2018-05-14 | ||
| US62/671,166 | 2018-05-14 | ||
| PCT/US2019/032002 WO2019222093A1 (en) | 2018-05-14 | 2019-05-13 | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024031206A Division JP2024051160A (ja) | 2018-05-14 | 2024-03-01 | ピリミジン誘導体の医薬塩及び障害の処置方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021523208A JP2021523208A (ja) | 2021-09-02 |
| JP2021523208A5 true JP2021523208A5 (enExample) | 2022-05-20 |
Family
ID=68540756
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564227A Pending JP2021523208A (ja) | 2018-05-14 | 2019-05-13 | ピリミジン誘導体の医薬塩及び障害の処置方法 |
| JP2024031206A Pending JP2024051160A (ja) | 2018-05-14 | 2024-03-01 | ピリミジン誘導体の医薬塩及び障害の処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024031206A Pending JP2024051160A (ja) | 2018-05-14 | 2024-03-01 | ピリミジン誘導体の医薬塩及び障害の処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12084431B2 (enExample) |
| EP (2) | EP4234547A3 (enExample) |
| JP (2) | JP2021523208A (enExample) |
| KR (1) | KR20200144579A (enExample) |
| CN (1) | CN112313223A (enExample) |
| AU (1) | AU2019269372A1 (enExample) |
| BR (1) | BR112020023107A2 (enExample) |
| CA (1) | CA3099737A1 (enExample) |
| MX (1) | MX2020012063A (enExample) |
| TW (1) | TWI831780B (enExample) |
| WO (1) | WO2019222093A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020240382B2 (en) | 2019-03-19 | 2022-08-25 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| KR20220011663A (ko) * | 2019-05-22 | 2022-01-28 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 인돌 유도체-함유 억제제, 이의 제조 방법 또는 이의 적용 |
| CN111303125A (zh) * | 2020-04-10 | 2020-06-19 | 天津法莫西医药科技有限公司 | 一种甲氧基取代吲哚-嘧啶类化合物及其制备方法 |
| CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
| WO2023277172A1 (en) | 2021-06-30 | 2023-01-05 | Takeda Pharmaceutical Company Limited | Process for preparing pharmaceutical salts of pyrimidine derivatives |
| EP4367116A4 (en) * | 2021-07-07 | 2025-04-30 | Crimson Biopharm Inc. | Crystalline polymorphs of epidermal growth factor receptor inhibition, and compositions and methods therefor |
| MX2024000261A (es) * | 2021-08-06 | 2024-03-14 | Abbisko Therapeutics Co Ltd | Derivado de pirimidina o piridina, metodo de preparacion del mismo y aplicacion del mismo en la industria farmaceutica. |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3788629T2 (de) | 1986-03-31 | 1994-04-28 | Rhone Poulenc Bv | Neue malonsäurederivate und zusammensetzungen, die sie enthalten, zur verzögerung des pflanzenwachstums. |
| JP2749578B2 (ja) | 1986-03-31 | 1998-05-13 | ローヌープーラン・ネーデルランド・ベー・ベー | 相乗的植物成長調節剤組成物 |
| JPS63503070A (ja) | 1986-03-31 | 1988-11-10 | ローヌープーラン・ネーデルランド・ベー・ベー | マロン酸誘導体化合物の作物収穫量を増大させるための使用 |
| WO2000006555A1 (en) | 1998-07-30 | 2000-02-10 | American Home Products Corporation | Substituted quinazoline derivatives |
| SK9742002A3 (en) * | 2000-01-07 | 2003-02-04 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| WO2003097855A2 (en) | 2002-05-14 | 2003-11-27 | Baylor College Of Medicine | Small molecule inhibitors of her2 expression |
| GB0311274D0 (en) * | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| JP2008510719A (ja) | 2004-08-19 | 2008-04-10 | イコス・コーポレイション | Ｃｈｋ１の阻害に有用な化合物 |
| EP1951672B1 (en) | 2005-10-21 | 2011-05-25 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| PL1948180T3 (pl) | 2005-11-11 | 2013-09-30 | Boehringer Ingelheim Int | Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2 |
| TW200826843A (en) | 2006-09-13 | 2008-07-01 | Sumitomo Chemical Co | Thiadiazole compound and use thereof |
| FR2911140B1 (fr) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| FR2911138B1 (fr) | 2007-01-05 | 2009-02-20 | Sanofi Aventis Sa | Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| FR2911139A1 (fr) | 2007-01-05 | 2008-07-11 | Sanofi Aventis Sa | Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| CA2690334C (en) | 2007-06-08 | 2017-02-14 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| WO2009003998A2 (en) | 2007-07-02 | 2009-01-08 | Boehringer Ingelheim International Gmbh | Antiproliferative compounds based on 5-membered heterocycles |
| FR2919869B1 (fr) | 2007-08-09 | 2009-09-25 | Sanofi Aventis Sa | Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
| NZ603525A (en) | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| CN101723936B (zh) | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | 激酶抑制剂及其在药学中的用途 |
| JP2012517448A (ja) | 2009-02-11 | 2012-08-02 | リアクション バイオロジー コープ． | 選択的キナーゼ阻害剤 |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| JP5918693B2 (ja) * | 2009-05-05 | 2016-05-18 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｅｇｆｒ阻害剤及び疾患の治療方法 |
| EP2430013B1 (en) | 2009-05-13 | 2014-10-15 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
| US8563567B2 (en) | 2009-12-30 | 2013-10-22 | Arqule, Inc. | Substituted heterocyclic compounds |
| WO2012020215A1 (en) | 2010-08-09 | 2012-02-16 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| WO2012068440A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors |
| EP2710003A1 (en) | 2011-05-16 | 2014-03-26 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
| MY161925A (en) | 2011-07-27 | 2017-05-15 | Astrazeneca Ab | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
| WO2013170113A1 (en) | 2012-05-11 | 2013-11-14 | Abbvie Inc. | Nampt inhibitors |
| AR091023A1 (es) | 2012-05-11 | 2014-12-30 | Abbvie Inc | Inhibidores del nampt |
| US20140371238A1 (en) | 2013-03-13 | 2014-12-18 | Flatley Discovery Lab | Compounds and methods for the treatment of cystic fibrosis |
| CN104262328B (zh) | 2013-09-18 | 2016-09-07 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
| US9840517B2 (en) | 2013-09-18 | 2017-12-12 | Beijing Hanmi Pharmaceutical Co., Ltd. | Compound inhibiting activities of BTK and/or JAK3 kinases |
| CN104860941B (zh) | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| JP2017507983A (ja) | 2014-03-18 | 2017-03-23 | アイティーオス セラペウティクス | 新規な３−インドール置換誘導体、医薬組成物、および使用方法 |
| MY186839A (en) * | 2014-06-19 | 2021-08-25 | Takeda Pharmaceuticals Co | Heteroaryl compounds for kinase inhibition |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| PL3205650T3 (pl) | 2014-10-11 | 2021-12-06 | Shanghai Hansoh Biomedical Co., Ltd. | Inhibitor EGFR i jego otrzymywanie i zastosowanie |
| TWI696617B (zh) | 2015-04-28 | 2020-06-21 | 大陸商上海復尚慧創醫藥研究有限公司 | 特定蛋白質激酶抑制劑 |
| CN106995437A (zh) | 2016-01-22 | 2017-08-01 | 齐鲁制药有限公司 | 取代吲哚或吲唑嘧啶衍生物及其制备方法和用途 |
| CN110248934B (zh) * | 2016-09-12 | 2022-05-24 | 帕德罗科治疗公司 | 杂芳基pad4抑制剂 |
-
2019
- 2019-05-13 EP EP23179346.4A patent/EP4234547A3/en not_active Withdrawn
- 2019-05-13 WO PCT/US2019/032002 patent/WO2019222093A1/en not_active Ceased
- 2019-05-13 KR KR1020207035669A patent/KR20200144579A/ko not_active Ceased
- 2019-05-13 EP EP19804043.8A patent/EP3793993A4/en not_active Withdrawn
- 2019-05-13 US US17/055,164 patent/US12084431B2/en active Active
- 2019-05-13 CA CA3099737A patent/CA3099737A1/en active Pending
- 2019-05-13 BR BR112020023107-0A patent/BR112020023107A2/pt not_active Application Discontinuation
- 2019-05-13 MX MX2020012063A patent/MX2020012063A/es unknown
- 2019-05-13 JP JP2020564227A patent/JP2021523208A/ja active Pending
- 2019-05-13 CN CN201980042034.8A patent/CN112313223A/zh active Pending
- 2019-05-13 AU AU2019269372A patent/AU2019269372A1/en not_active Abandoned
- 2019-05-14 TW TW108116512A patent/TWI831780B/zh not_active IP Right Cessation
-
2024
- 2024-03-01 JP JP2024031206A patent/JP2024051160A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3160899C (en) | Spiro compound serving as erk inhibitor, and application thereof | |
| EP4282416A2 (en) | Process of manufacture of a compound for inhibiting the activity of shp2 | |
| JP7841008B2 (ja) | セピアプテリンの薬学的に許容される塩 | |
| ES2290281T5 (es) | Sal de succinato de O-desmetil-venlafaxina | |
| JP2023062189A (ja) | 癌を処置する方法 | |
| CA2981746C (en) | Maleate salts of a b-raf kinase inhibitor, crystalline forms, methods of preparation, and uses therefore | |
| JP6479970B2 (ja) | ウラシル化合物の新規結晶 | |
| CN119060066A (zh) | 取代的芳基或杂芳基并双环类抑制剂及其制备方法和应用 | |
| KR20080044841A (ko) | 이마티닙 메실레이트의 다형 및 신규한 결정형과 비결정형및 α형의 제조 방법 | |
| BR112015017963A2 (pt) | composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto | |
| CN105849108A (zh) | 磷脂酰肌醇3-激酶抑制剂的制备方法 | |
| BR112019020840A2 (pt) | sais farmacêuticos, formas físicas e composições de inibidores da pirrolopirimidina quinase e métodos de produção dos mesmos | |
| JP7659343B2 (ja) | ピロロピリミジン系化合物の塩、その結晶及びその使用 | |
| BR112020023107A2 (pt) | sais farmacêuticos de derivados de pirimidina e método de tratamento de distúrbios | |
| CN112142679A (zh) | 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法 | |
| MX2013010702A (es) | Nueva forma cristalina vii de la agomelatina, sus metodos de preparacion, aplicaciones y composiciones farmaceuticas que la contienen. | |
| BR112017024785B1 (pt) | Forma cristalina do composto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4] oxadiazol-3- il]-2-etil-6-metilfenoxi}-propano-1,2-diol, composição farmacêutica, e, uso | |
| CN114736214B (zh) | 一种倍半萜衍生物、其药物组合物及其制备方法和用途 | |
| US12252469B2 (en) | Crystalline forms of (E)-N-hydroxy-3-(1-(phenylsulfonyl)indolin-5-yl)acrylamide | |
| AU2024271907A1 (en) | Hdac1/2 selective inhibitor and use thereof | |
| JPS58208275A (ja) | ５−アミノ−ピラゾ−ル誘導体及び該化合物を含有する抗腫瘍剤 | |
| RU2020140818A (ru) | Фармацевтические соли производных пиримидина и способ лечения заболеваний | |
| CN104650109A (zh) | 紫杉烷类化合物 | |
| CN108864114B (zh) | 选择性a2a受体拮抗剂 | |
| AU2009321384A1 (en) | Polymorphs |